A dynamic immune response index combining C-reactive protein and lactate dehydrogenase kinetics is associated with outcomes of PD-1 inhibitor monotherapy in recurrent/metastatic nasopharyngeal carcinoma

The CRP-LDH-based IRI, both at baseline and during early treatment, is a practical tool for stratifying prognosis and dynamically monitoring response to PD-1 inhibitors in RM-NPC, which supports ongoing clinical evaluation.